Tag: Cabometyx prognosis for neuroendocrine tumors
Cabometyx: Positive Results in Treating Neuroendocrine Tumors (NET)
Ipsen Pharmaceuticals has recently announced positive final data from a phase 3 trial evaluating their drug cabozantinib, marketed as Cabometyx, in the treatment of pancreatic and extra-pancreatic neuroendocrine tumors (NET). This news marks a...